IP Library Granted Patent US 7,749,515
Granted Patent B2
US 7,749,515 · App. 12/136,503 · Granted Jul 6, 2010

Targeted delivery of botulinum toxin to the sphenopalatine ganglion

Assignee: Allergan, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,749,515
App. No.
12/136,503
Granted
Jul 6, 2010
Kind
B2
Abstract

Botulinum toxin, among other presynaptic neurotoxins is used for the treatment and prevention of migraine and other headaches associated with vascular disorders. Presynaptic neurotoxins are delivered focally, targeting the sphenopalatine ganglion. Exemplary delivery is carried out by way of injection.

Claims (27)

1. A method for reduction of headache pain in a mammal in need thereof comprising:

administering to a sphenopalatine ganglion, in a pharmaceutically safe form to a mammal, a therapeutically effective amount of a botutinum toxin thereby effecting reduction of headache pain in the mammal.

2. The method according to claim 1 , wherein the botulinum toxin is administered by injection.

3. The method according to claim 2 , wherein the botulinum toxin is selected from the group consisting of botulinum toxin type A, B, C 1 , D, L, F or G.

4. The method according to claim 3 wherein the botulinum toxin is botulinum toxin type A.

5. The method according to claim 2 wherein said administering step comprises the steps of:

identifying an injection site midway between the tragus of the ear and the outer cantus of the eye;

inserting a syringe at an angle of about 50-70 degrees relative to the vertical plane of the face;

stopping the forward motion of the syringe upon reaching the maxillary bone;

injecting the botulinum toxin at the sphenopalatine ganglion; and

withdrawing the syringe.

6. The method according to claim 5 wherein said botulinum toxin is injected in a discrete manner at a plurality of locations adjacent to the sphenopalatine ganglion.

7. The method according to claim 1 wherein said headache pain is associated with a headache selected from the group consisting of migraine, trigeminal autonomic cephalgia and headache caused by a vascular condition.

8. The method according to claim 1 wherein said administering step is performed bilaterally.

9. The method according to claim 1 wherein said administering step is performed unilaterally.

10. A method for reduction of headache pain in a mammal in need thereof comprising:

administering by injection to a sphenopalatine ganglion, in a pharmaceutically safe form to a mammal, a therapeutically effective amount of botulinum toxin type A, thereby effecting reduction of headache pain in the mammal.

11. The method according to claim 10 wherein said headache pain is associated with a headache selected from the group consisting of migraine, trigeminal autonomic cephalgia and headache caused by a vascular condition.

12. The method according to claim 10 wherein said administering step comprises the steps of:

identifying an injection site midway between the tragus of the ear and the outer cantus of the eye;

inserting a syringe at an angle of about 50-70 degrees relative to the vertical plane of the face;

stopping the forward motion of the syringe upon reaching the maxillary bone;

injecting the botulinum toxin type A at the sphenopalatine ganglion; and

withdrawing the syringe.

13. The method according to claim 12 wherein said botulinum toxin type A is injected a discrete manner at a plurality of locations adjacent to the sphenopalatine ganglion.

14. The method according to claim 10 wherein said administering step is performed bilaterally.

15. The method according to claim 10 wherein said administering step is performed unilaterally.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 9, 2008
From: BLUMENFELD, ANDREW
To: ALLERGAN, INC.
Reel/Frame 021214/0971 →
Continuity (3)
Continuation In Part 1129607900 · Dec 7, 2005
Provisional Application 6059364100 · Feb 1, 2005
Related Publication 20080279895A1 · Nov 13, 2008